KMD Bioscience Co., Ltd.
400-621-6806
Service Line：+1-315-239-3085
Address：FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
To achieve a certain therapeutic effect in vivo, the antibody affinity needs to reach a certain level. In addition, the antibody affinity decreased obviously after humanization. Therefore, it is necessary to increase the antibody affinity of humanized antibodies to the pre-humanized level. Affinity maturation is a common strategy to improve the antigen-antibody binding affinity. KMD Bioscience has established a mature antibody production platform with advanced antibody engineering technology. KMD Bioscience offers antibody affinity maturation service that can improve the affinity of antibodies to the desired level.
Supported by our well-established antibody phage display library, KMD Bioscience can provide multi species antibody affinity maturation service. Together with our experienced scientists in antibody affinity maturation, KMD Bioscience can make the affinity of monoclonal antibodies reach 10-9M. Better quality antibodies to make your research easier.
Antibody affinity maturation and affinity drug screening are interrelated concepts crucial for developing therapeutic antibodies. Affinity maturation optimizes antibody efficacy, while affinity drug screening identifies antibodies with desired affinity characteristics for drug development. Screening diverse antibody variants using high-throughput techniques like phage display or yeast surface display efficiently identifies lead candidates with superior binding affinity. By combining affinity maturation and drug screening, KMD Bioscience scientists iteratively improve antibody affinity through somatic hypermutation and screening assays. This approach generates optimized antibodies with enhanced affinity for targeted therapeutics. Antibody affinity maturation improves binding affinity, and affinity drug screening selects antibodies with desirable affinities, contributing to the development of high-affinity therapeutic antibodies.
Antibody Affinity Maturation:
Affinity maturation is the process by which TFH cell-activated B cells produce antibodies with increased affinity for antigens during an immune response. It is a crucial step in the immune response to ensure the generation of antibodies that effectively bind and neutralize the target antigen. Successive generations of B cells mutate and present to the antigen, that recognizes the antigen with high affinity will survive, and the low-affinity ones are eliminated. KMD Bioscience uses phage display library technology, and combined with error-prone PCR and site-directed mutagenesis, we were able to mimic these over-frequency cellular mutations. Our technical advantage lies in the ability to mutate rapidly in vitro and construct more than 1010 independent clones of antibody phage display libraries, so that high specificity and affinity antibodies can be obtained in a short time.
Antibody affinity maturation involves somatic hypermutation (SHM) of B-cell immunoglobulin genes, resulting in multiple antibody variants that are selected based on antigen binding for increased affinity. This process occurs in germinal centers within secondary lymphoid tissues, where B-cells undergo rounds of proliferation, mutation, and selection. Selection for antigen binding leads to the preferential expansion and differentiation of B-cells with higher-affinity antibodies. In vitro techniques, such as directed evolution or rational design, can guide affinity maturation to generate antibodies with desired properties.
Antibody Affinity Maturation Service Process:
Common Affinity Maturation Techniques:
Different methods of mutagenesis offer diverse strategies to optimize antibody affinity. Random mutagenesis provides a broad range of mutations, while targeted mutagenesis focuses on specific regions such as CDRs. Chain shuffling generate libraries of diverse variants, enabling the selection of higher-affinity binders.
--Targeted mutagenesis, involves introducing specific mutations into predetermined regions of a DNA sequence. In the context of immunoglobulin genes, targeted mutagenesis often focuses on the complementarity-determining regions (CDRs). These regions are responsible for the binding of antibodies to their target antigens. By introducing mutations in the CDRs, researchers can fine-tune the binding specificity and affinity of antibodies to enhance their therapeutic or diagnostic potential.
--Random mutagenesis is a technique used to introduce a wide range of unbiased mutations into a DNA sequence. This can be achieved through methods such as error-prone polymerase chain reaction (PCR) or DNA shuffling. Error-prone PCR utilizes DNA polymerases with reduced fidelity, leading to an increased rate of errors during DNA replication. This results in the introduction of random mutations throughout the DNA sequence. This method allows the construction of large libraries containing 108 starting from 3 to 10 selected antibodies.
--Chain shuffling is a technique used to diversify the sequence of an antibody. It involves the creation of a library of mutant antibody genes, which are then displayed on filamentous phage particles. The phage display system allows for the selection of higher-affinity binders by exposing the phage library to the target antigen. Through an iterative process of binding and enrichment, antibodies with improved affinity can be isolated and further characterized.
Deliverable:
--Affinity optimized antibodies sequences.
--Purified antibody with high affinity.
--Comprehensive report and data: including SDS-PAGE and affinity analysis, etc.
Antibody Affinity Maturation Service Highlights:
--Extensive experience and strong track record in antibody affinity maturation
--Improve the affinity up to 10-9M
--A variety of methods to ensure a high success rate
--Strict quality control
--Various antibody library searching strategies are available
--One-stop services, including antibody development, antibody sequencing, antibody labeling, antibody humanization and related services
How to Order?
If you have any questions regarding our services or products, please feel free to contact us by E-mail: info@kmdbioscience.com or Tel: +86-400-621-6806;
FL-4, Building A5, International Enterprise Community, Tianjin, China
Email：info@kmdbioscience.com
Hot Line： +1-315-239-3085
Technical Support：sales@kmdbiosci.com
